NCT03772899
Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)
StatusActive, Not Recruiting
PhasePhase 1
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 29 words
- Study completion pushed from Aug 2026 to Feb 2027
- Secondary endpoints: details revised at 2 of 7 entries
- Publications: details revised at 1 of 1 entry
- Minor Study completion date: Dec 2024 to Aug 2026v10
- Minor Primary completion date changed from estimate of Dec 2023 to Sep 14, 2021
- Study completion date: Dec 2023 to Dec 2024
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 3 of 3 sites
- Minor Study sites: 1 to 3
- Secondary endpoints: 4 to 7
- Study arms: 0 to 1
Show 2 earlier versionsHide 2 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Apr 2019 to Mar 27, 2019
- Notable Start date: Dec 2018 to Apr 2019v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To evaluate the safety of combining Fecal Microbial Transplantation (FMT) using intestinal bacteria existing in the stool of healthy donors with immunotherapy in melanoma patients.
Timeframe: 60 months
Secondary (4)
Assess Objective Response Rate
To Evaluate the effect(s) combination FMT and immunotherapy has on the gut microbiome
Evaluate the effect(s) combination FMT and immunotherapy has on changes in immune blood biomarkers
Evaluate the effect(s) combination FMT and immunotherapy has on patient's metabolomics
Arms and interventions
Study InterventionExperimental
Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
Drugs: Fecal Microbial Transplantation
Sites
3 sites in 1 country